Medtronic Needs to Regrow a Spine

By · February 25, 2010 · No comments
Spine · Tagged: , ,

Medtronic's (NYSE: MDT) third-fiscal-quarter revenue chart would make a good preschool test for finding the outlier. (Hint: Look for the parentheses.)

Segment Sales (in Millions) Increase (Decrease) at Constant Currencies
Cardiac rhythm disease management $1,243 2%
Spinal $842 (1%)
Cardiovascular $722 21%
Neuromodulation $394 8%
Diabetes $311 8%
Surgical technologies $239 12%
Physio-control $100 8%

To read more please CLICK HERE

Source: Company press release.

Posted By

Josh Sandberg has been recruiting specifically in the musculoskeletal industry for over 8 years. Throughout this time, he has been able to have a positive impact on his client’s businesses. With an educational background in Business Management, Josh is adept to discern which people will be the best fit for the company he is searching for by understanding how candidates will incorporate with the company’s culture and operational nuances. His experience as an executive in a start-up business has granted him the ability to understand what is takes to thrive in a hands–on environment, where desire and dedication are paramount for success.
←
→

© 2012 OrthoSpineNews